{"id":4233,"date":"2024-10-11T15:29:39","date_gmt":"2024-10-11T13:29:39","guid":{"rendered":"http:\/\/blog.lallianse.com\/?p=4233"},"modified":"2025-10-22T15:15:05","modified_gmt":"2025-10-22T13:15:05","slug":"bpifrance-le-hub-x-fabentech-x-lallianse-2","status":"publish","type":"post","link":"https:\/\/blog.lallianse.com\/index.php\/en\/bpifrance-le-hub-x-fabentech-x-lallianse-2\/","title":{"rendered":"Fabentech x LallianSe"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-text-color has-link-color has-medium-font-size wp-elements-a03812a21b4499c15a9eafe5bec7a193\" style=\"color:#d1b04c\"><strong>October 8th, 2024<\/strong><\/h2>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-7d4c2c6e76b8b71a97c1655f503f1d25\" style=\"color:#546a7b\">\ud83c\udf89A  20 M\u20ac <strong>#milestone<\/strong>\u00a0! \ud83c\udf89<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-632223dfe0e92a614f0c9a6b6e3194d1\" style=\"color:#546a7b\"><a href=\"https:\/\/www.linkedin.com\/company\/fab'entech\/posts\/?feedView=all#\" target=\"_blank\" rel=\"noreferrer noopener\">Fabentech<\/a> continues its trajectory and completes the first steps of its <strong>#equitystory<\/strong> !<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-20789c043608871abfda9b79941f249b\" style=\"color:#546a7b\">A French <strong>#biopharmaceutical<\/strong> company specializing in the development and production of therapeutic products against biological threats, Fabentech has just announced support of up to \u20ac20M from the <a href=\"https:\/\/www.linkedin.com\/company\/fab'entech\/posts\/?feedView=all#\" target=\"_blank\" rel=\"noreferrer noopener\">European Investment Bank (EIB)<\/a>\u00a0through <strong>#HERAInvest<\/strong> program.<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-1d10d9b13a3fe0ff8c8ad8b78da2ec32\" style=\"color:#546a7b\">Beyond strengthening #R&amp;D capacities, this allows to increase industrial efforts and international impact. A key step forward in global preparedness against biological and bioterrorist threats.<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-1bd86ec7ed22f336833e1fc41e081d1e\" style=\"color:#546a7b\">Happy to have finalized this transaction with <a href=\"https:\/\/www.linkedin.com\/company\/fab'entech\/posts\/?feedView=all#\" target=\"_blank\" rel=\"noreferrer noopener\">Jeremy Ballet<\/a>.<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-ab08371cae49f7459d295bbd4ac288b5\" style=\"color:#546a7b\">\ud83d\udc4f We take on challenges together, and celebrate victories together. Congratulations to <a href=\"https:\/\/www.linkedin.com\/company\/fab'entech\/posts\/?feedView=all#\" target=\"_blank\" rel=\"noreferrer noopener\">S\u00e9bastien IVA<\/a> and the entire team for this major milestone.\u00a0<\/p>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-afbdd867b984cea614e5456e3c5781bd\" style=\"color:#546a7b\">\u00a0<strong>#Investment<\/strong> <strong>#EIBFinancing<\/strong> <strong>#FabShield\u00ae<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-color has-link-color has-medium-font-size wp-elements-83a006911cee67faf7ddeb8dc1a7dc61\" style=\"color:#d1b04c\"><strong>February 5th, 2024<\/strong><\/h2>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">For almost 4 years now, the relationship driven by <a href=\"https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7159164024524316672\/?actorCompanyId=11090258#\" target=\"_blank\" rel=\"noreferrer noopener\">Bpifrance Le Hub<\/a> between<a href=\"https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7159164024524316672\/?actorCompanyId=11090258#\" target=\"_blank\" rel=\"noreferrer noopener\">Fab\u2019entech<\/a> and <a href=\"https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7159164024524316672\/?actorCompanyId=11090258#\" target=\"_blank\" rel=\"noreferrer noopener\">LallianSe \u2013 Life Sciences Integrator<\/a> has been enriched and developed.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Initiated as <strong>#SparringPartner<\/strong> following the arrival of  <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7159164024524316672\/?actorCompanyId=11090258#\" target=\"_blank\">S\u00e9bastien IVA<\/a> as Chairman of the Management Board in 2020, the translation of the vision, the outline of the roadmap and the articulation of the investment thesis have gradually strengthened the agenda of interactions and existing support.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">A real pleasure to support the evolution of <strong>#Fabentech<\/strong> towards its position as European leader!<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Discover all of our feedback here \ud83d\udc49 <a rel=\"noreferrer noopener\" href=\"https:\/\/lehub.bpifrance.fr\/mission-operating-partner-retour-dexperience-dune-methodologie-eprouvee-par-lallianse-lexemple-de-fabentech\/?utm_source=linkedin&amp;utm_medium=post&amp;utm_campaign=lehubonline\" target=\"_blank\">link to the interview<\/a><\/p>\n\n\n\n<iframe loading=\"lazy\" src=\"https:\/\/www.linkedin.com\/embed\/feed\/update\/urn:li:share:7159164023639277569\" height=\"1023\" width=\"504\" frameborder=\"0\" allowfullscreen=\"\" title=\"Post int\u00e9gr\u00e9\"><\/iframe>\n","protected":false},"excerpt":{"rendered":"<p>October 8th, 2024 \ud83c\udf89A 20 M\u20ac #milestone\u00a0! \ud83c\udf89 Fabentech continues its trajectory and completes the first steps of its #equitystory ! A French #biopharmaceutical company specializing in the development and production of therapeutic products against biological threats, Fabentech has just announced support of up to \u20ac20M from the European Investment Bank (EIB)\u00a0through #HERAInvest program. Beyond &hellip; <a href=\"https:\/\/blog.lallianse.com\/index.php\/en\/bpifrance-le-hub-x-fabentech-x-lallianse-2\/\" class=\"more-link\">Continuer la lecture<span class=\"screen-reader-text\"> de &laquo;&nbsp;Fabentech x LallianSe&nbsp;&raquo;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[246,240],"tags":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4233"}],"collection":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/comments?post=4233"}],"version-history":[{"count":5,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4233\/revisions"}],"predecessor-version":[{"id":4602,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4233\/revisions\/4602"}],"wp:attachment":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/media?parent=4233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/categories?post=4233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/tags?post=4233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}